More and more studies have reported changes in PTEN and the interplay with other genes studied in mouse models of prostate cancer has been shown to collectively shape the immune cell content and expression of immunosuppressive markers in the tumor microenvironment [37,38], providing a strong rationale for investigating similar strategies in patients with OCCC with this molecular profile. Here, PTEN is linked to prostate carcinoma.